Raju Khatri1, John K Fallon2, Rebecca J B Rementer1, Natasha T Kulick1, Craig R Lee1, Philip C Smith3. 1. Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, United States of America. 2. Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, United States of America. 3. Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, United States of America. Electronic address: pcs@email.unc.edu.
Abstract
INTRODUCTION: Sandwich-cultured human hepatocytes (SCHHs) are the most common in vitro hepatocyte model used for studying hepatic drug disposition and hepatotoxicity. Targeted quantification of key DME and transporter protein expression is useful for in vitro-in vivo extrapolation of drug and xenobiotic clearance and developing corresponding PBPK models. However, established methods for comprehensive quantification of drug metabolizing enzyme (DMEs) and transporter expression in SCHHs are lacking. In this study, a targeted quantitative proteomic isotope dilution nanoLC-MS/MS method developed in our laboratory was adapted to quantify a panel of phase I & II DMEs and transporter proteins in SCHHs under basal and induced conditions. METHODS: SCHHs were treated with known inducers of DMEs (Rifampin: PXR activator, CITCO: CAR activator) and transporters (CDCA: FXR activator) or with vehicle control (DMSO) for 72 h. Membrane protein was isolated from the SCHHs using a membrane extraction kit and 30 μg membrane protein was digested with trypsin. The resulting peptides were analyzed by isotope dilution nanoLC-MS/MS to quantify the DMEs and transporters. RESULTS: Using the method, we could quantify fourteen phase I and ten phase II DMEs, and twelve uptake/efflux transporters, under basal and induced conditions in the SCHHs. Analysis showed donor to donor variation in basal protein levels of CYP450s, UGTs and transporters, and that basal protein expression of CYP450s and UGTs was higher than that of transporters. In addition, induction of key proteins in response to rifampin, CITCO and CDCA was observed. DISCUSSION: We have successfully quantified protein abundance of multiple phase I and II DMEs and uptake and efflux transporters in SCHHs using a method previously developed in our laboratory. Our method is sufficiently sensitive to quantify inter-donor differences in protein concentrations at the basal level as well as changes in protein expression in response to endogenous and exogenous stimuli.
INTRODUCTION: Sandwich-cultured human hepatocytes (SCHHs) are the most common in vitro hepatocyte model used for studying hepatic drug disposition and hepatotoxicity. Targeted quantification of key DME and transporter protein expression is useful for in vitro-in vivo extrapolation of drug and xenobiotic clearance and developing corresponding PBPK models. However, established methods for comprehensive quantification of drug metabolizing enzyme (DMEs) and transporter expression in SCHHs are lacking. In this study, a targeted quantitative proteomic isotope dilution nanoLC-MS/MS method developed in our laboratory was adapted to quantify a panel of phase I & II DMEs and transporter proteins in SCHHs under basal and induced conditions. METHODS: SCHHs were treated with known inducers of DMEs (Rifampin: PXR activator, CITCO: CAR activator) and transporters (CDCA: FXR activator) or with vehicle control (DMSO) for 72 h. Membrane protein was isolated from the SCHHs using a membrane extraction kit and 30 μg membrane protein was digested with trypsin. The resulting peptides were analyzed by isotope dilution nanoLC-MS/MS to quantify the DMEs and transporters. RESULTS: Using the method, we could quantify fourteen phase I and ten phase II DMEs, and twelve uptake/efflux transporters, under basal and induced conditions in the SCHHs. Analysis showed donor to donor variation in basal protein levels of CYP450s, UGTs and transporters, and that basal protein expression of CYP450s and UGTs was higher than that of transporters. In addition, induction of key proteins in response to rifampin, CITCO and CDCA was observed. DISCUSSION: We have successfully quantified protein abundance of multiple phase I and II DMEs and uptake and efflux transporters in SCHHs using a method previously developed in our laboratory. Our method is sufficiently sensitive to quantify inter-donor differences in protein concentrations at the basal level as well as changes in protein expression in response to endogenous and exogenous stimuli.
Authors: Anne-Mari Moilanen; Jukka Hakkola; Markku H Vaarala; Saila Kauppila; Pasi Hirvikoski; Jussi T Vuoristo; Robert J Edwards; Timo K Paavonen Journal: Carcinogenesis Date: 2006-11-20 Impact factor: 4.944
Authors: M Makishima; A Y Okamoto; J J Repa; H Tu; R M Learned; A Luk; M V Hull; K D Lustig; D J Mangelsdorf; B Shan Journal: Science Date: 1999-05-21 Impact factor: 47.728
Authors: D J Parks; S G Blanchard; R K Bledsoe; G Chandra; T G Consler; S A Kliewer; J B Stimmel; T M Willson; A M Zavacki; D D Moore; J M Lehmann Journal: Science Date: 1999-05-21 Impact factor: 47.728
Authors: Jodi M Maglich; Derek J Parks; Linda B Moore; Jon L Collins; Bryan Goodwin; Andrew N Billin; Catherine A Stoltz; Steven A Kliewer; Millard H Lambert; Timothy M Willson; John T Moore Journal: J Biol Chem Date: 2003-02-27 Impact factor: 5.157
Authors: Aaron S Devanathan; John K Fallon; Nicole R White; Amanda P Schauer; Brian Van Horne; Kimberly Blake; Craig Sykes; Martina Kovarova; Lourdes Adamson; Leila Remling-Mulder; Paul Luciw; J Victor Garcia; Ramesh Akkina; Jason R Pirone; Philip C Smith; Angela D M Kashuba Journal: Antimicrob Agents Chemother Date: 2020-09-21 Impact factor: 5.191
Authors: Bridget L Morse; John K Fallon; Anil Kolur; Andrew T Hogan; Philip C Smith; Kathleen M Hillgren Journal: AAPS J Date: 2021-04-26 Impact factor: 4.009
Authors: Matthew J Haney; Yuling Zhao; John K Fallon; Wang Yue; Samuel M Li; Emily E Lentz; Dorothy Erie; Philip C Smith; Elena V Batrakova Journal: Adv Nanobiomed Res Date: 2021-06-29
Authors: Philip Sandoval; Bei-Ching Chuang; John K Fallon; Philip C Smith; Swapan K Chowdhury; Robert J Griffin; Cindy Q Xia; Shinji Iwasaki; Paresh P Chothe Journal: AAPS J Date: 2022-09-19 Impact factor: 3.603
Authors: James J Beaudoin; Jacqueline Bezençon; Noora Sjöstedt; John K Fallon; Kim L R Brouwer Journal: Toxicol Sci Date: 2020-07-01 Impact factor: 4.849
Authors: Raju Khatri; John K Fallon; Craig Sykes; Natasha Kulick; Rebecca J B Rementer; Taryn A Miner; Amanda P Schauer; Angela D M Kashuba; Kim A Boggess; Kim L R Brouwer; Philip C Smith; Craig R Lee Journal: Front Pharmacol Date: 2021-04-15 Impact factor: 5.810
Authors: Jacqueline Bezençon; Chitra Saran; Janine Hussner; James J Beaudoin; Yueping Zhang; Hong Shen; John K Fallon; Philip C Smith; Henriette E Meyer Zu Schwabedissen; Kim L R Brouwer Journal: J Pharm Sci Date: 2020-10-13 Impact factor: 3.534
Authors: Raju Khatri; Natasha Kulick; Rebecca J B Rementer; John K Fallon; Craig Sykes; Amanda P Schauer; Melina M Malinen; Merrie Mosedale; Paul B Watkins; Angela D M Kashuba; Kim A Boggess; Philip C Smith; Kim L R Brouwer; Craig R Lee Journal: J Pharm Sci Date: 2020-09-12 Impact factor: 3.534
Authors: Manisha Nautiyal; Rani J Qasem; John K Fallon; Kristina K Wolf; Jingli Liu; Darlene Dixon; Philip C Smith; Merrie Mosedale Journal: Toxicol In Vitro Date: 2020-10-03 Impact factor: 3.500